Filing Details

Accession Number:
0001104659-24-090984
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-19 20:14:28
Reporting Period:
2024-08-15
Accepted Time:
2024-08-19 20:14:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609550 Inspire Medical Systems Inc. INSP Surgical & Medical Instruments & Apparatus (3841) 261377674
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1737127 Randy Ban C/O Inspire Medical Systems, Inc.
5500 Wayzata Blvd., Suite 1600
Golden Valley MN 55416
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-15 16,139 $42.15 19,195 No 4 M Direct
Common Stock Disposition 2024-08-15 776 $189.06 18,419 No 4 S Direct
Common Stock Disposition 2024-08-15 1,659 $190.20 16,760 No 4 S Direct
Common Stock Disposition 2024-08-15 2,072 $191.92 14,688 No 4 S Direct
Common Stock Disposition 2024-08-15 1,150 $192.60 13,538 No 4 S Direct
Common Stock Disposition 2024-08-15 8,132 $193.92 5,406 No 4 S Direct
Common Stock Disposition 2024-08-15 2,350 $194.91 3,056 No 4 S Direct
Common Stock Acquisiton 2024-08-16 4,861 $42.15 7,917 No 4 M Direct
Common Stock Disposition 2024-08-16 900 $187.10 7,017 No 4 S Direct
Common Stock Disposition 2024-08-16 3,066 $188.66 3,951 No 4 S Direct
Common Stock Disposition 2024-08-16 895 $189.64 3,056 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-08-15 16,139 $0.00 16,139 $42.15
Common Stock Stock Option (Right to Buy) Disposition 2024-08-16 4,861 $0.00 4,861 $42.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,861 2028-12-18 No 4 M Direct
0 2028-12-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 167 Indirect By son
Common Stock 166 Indirect By daughter
Footnotes
  1. Includes 27 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan since the Reporting Person's Form 4 dated February 27, 2024.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.995 to $189.285. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.08 to $190.845. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.225 to $192.18. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.26 to $193.22. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.4 to $194.32. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.81 to $195.15. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.90 to $187.71. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.255 to $189.24. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote .
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.26 to $189.855. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. The option is fully vested and exercisable.